Stock Traders Purchase Large Volume of Put Options on Definium Therapeutics (NASDAQ:DFTX)

Definium Therapeutics, Inc. (NASDAQ:DFTX) was the target of some unusual options trading on Monday. Investors bought 6,567 put options on the stock. This is an increase of approximately 68% compared to the average volume of 3,899 put options.

Definium Therapeutics Price Performance

Shares of DFTX stock traded up $1.70 during trading hours on Monday, reaching $40.59. The company’s stock had a trading volume of 4,431,703 shares, compared to its average volume of 2,238,051. Definium Therapeutics has a fifty-two week low of $8.77 and a fifty-two week high of $49.70. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The firm’s 50 day simple moving average is $43.01 and its 200-day simple moving average is $30.33. The company has a market capitalization of $5.45 billion, a price-to-earnings ratio of -11.83 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). Sell-side analysts forecast that Definium Therapeutics will post -3.02 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Mark Sullivan sold 13,008 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the sale, the insider owned 320,571 shares in the company, valued at approximately $14,435,312.13. The trade was a 3.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Brandi Roberts sold 3,013 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the sale, the chief financial officer owned 209,487 shares of the company’s stock, valued at $9,433,199.61. This trade represents a 1.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 67,119 shares of company stock worth $2,887,496 in the last quarter. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in DFTX. California State Teachers Retirement System bought a new position in shares of Definium Therapeutics during the second quarter valued at $283,999,000. Avoro Capital Advisors LLC acquired a new position in shares of Definium Therapeutics during the 4th quarter valued at $66,950,000. Wellington Management Group LLP bought a new position in Definium Therapeutics during the second quarter worth $138,755,000. Janus Henderson Group PLC boosted its stake in Definium Therapeutics by 8,513.2% during the fourth quarter. Janus Henderson Group PLC now owns 2,411,696 shares of the company’s stock worth $32,256,000 after acquiring an additional 2,383,696 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in Definium Therapeutics in the fourth quarter worth $17,516,000. Institutional investors own 27.91% of the company’s stock.

More Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported that its second Phase 3 study of DT120 ODT met its primary endpoint, showing a statistically significant improvement in anxiety symptoms among patients with generalized anxiety disorder. The result confirms the positive findings from the earlier late-stage study and reduces clinical-development risk. Definium’s LSD-based drug lowers anxiety in second successful late-stage study
• Positive Sentiment: Coverage of the Panorama Phase 3 trial highlighted significant anxiety improvement and described the data as a successful readout, helping drive renewed investor interest in DFTX. Definium Says Second Phase 3 DT120 Study in Generalized Anxiety Disorder Meets Goal
• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $70 price target, while Needham reaffirmed its “buy” rating with a $66 target. Both targets imply substantial upside from recent trading levels and indicate continued analyst confidence in DT120’s prospects.
• Positive Sentiment: Definium’s shares rallied as investors anticipated—and then reacted to—the Phase 3 results, with trading temporarily halted for pending news before the clinical announcement.
• Neutral Sentiment: The company granted stock options covering 56,650 shares to three newly hired, non-executive employees. The grants support hiring but could modestly increase future share dilution. Definium Therapeutics Announces New Employee Inducement Grants

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Leerink Partners set a $52.00 price objective on Definium Therapeutics and gave the stock an “outperform” rating in a report on Monday, June 22nd. Maxim Group set a $55.00 price objective on Definium Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 14th. Needham & Company LLC restated a “buy” rating and issued a $66.00 price objective on shares of Definium Therapeutics in a report on Monday. Royal Bank Of Canada restated an “outperform” rating and set a $66.00 target price on shares of Definium Therapeutics in a report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Definium Therapeutics in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Definium Therapeutics currently has an average rating of “Buy” and a consensus price target of $63.00.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.